Sellas Life Sciences Group Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Find out what a historical investment in Sellas Life Sciences Group Inc would be worth today using our SLS stock calculator.
$289.16M
-
0.00%
5.73M
$2.12
$1.99
$2.04
$2.48
$0.77
Ready to start your investing journey with Stake?
Open an accountSLS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in SLS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in SLS
on Stake
Buy SLS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of SLS from only US$10 with fractional shares
